Geftinat 250 mg tablet

Product Description

Geftinat 250 mg tablets are a targeted therapy designed to treat non-small cell lung cancer (NSCLC) that has metastasized in patients with specific mutations in the EGFR gene who have not undergone prior treatment for their cancer. This medication works by inhibiting the activity of the epidermal growth factor receptor, thereby slowing tumor growth and progression. It is important to note that Geftinat is not approved for use in pediatric patients due to insufficient evidence regarding its safety and efficacy in children and adolescents. While Geftinat can be an effective option for eligible adults, potential side effects may include skin rashes, diarrhea, and liver function abnormalities, necessitating regular monitoring by healthcare professionals. Patients should be aware of these possible reactions and discuss any concerns with their physician before starting treatment. This medication represents a significant advancement in targeted cancer therapy, offering hope to individuals battling advanced NSCLC. As with all cancer therapies, adherence to prescribed regimens and follow-up appointments is crucial for optimal outcomes.